Cargando…

Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer

INTRODUCTION: This multicenter phase II study determined the efficacy and safety of new daily oral S-1 and weekly irinotecan (CPT-11) combination schedule in patients with previously untreated advanced or recurrent colorectal cancer. PATIENTS AND METHODS: Patients received first-line chemotherapy co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogata, Yutaka, Tanaka, Takaho, Akagi, Yoshito, Ishibashi, Nobuya, Tsuji, Yoshiaki, Matono, Keiko, Isobe, Makoto, Sueyoshi, Susumu, Kaibara, Atsushi, Shirouzu, Kazuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572922/ https://www.ncbi.nlm.nih.gov/pubmed/23439317 http://dx.doi.org/10.4137/CMO.S10769

Ejemplares similares

Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells
por: USHIJIMA, MASATAKA, et al.
Publicado: (2014)

Randomized Phase II Study of 5-Fluorouracil Hepatic Arterial Infusion with or without Antineoplastons as an Adjuvant Therapy after Hepatectomy for Liver Metastases from Colorectal Cancer
por: Ogata, Yutaka, et al.
Publicado: (2015)

Clinicopathological evaluation of anoxic mucosal injury in strangulation ileus
por: Takahashi, Ryuji, et al.
Publicado: (2014)

Identification of high-risk factors as indicators for adjuvant therapy in stage II colon cancer patients treated at a single institution
por: YAMAGUCHI, KEIZO, et al.
Publicado: (2013)

A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)
por: Ogata, Yutaka, et al.
Publicado: (2015)

Extramural extension as indicator for postoperative adjuvant chemotherapy in Stage IIA (pT3N0) colon cancer
por: Akagi, Yoshito, et al.
Publicado: (2013)

Intersphincteric resection for very low rectal cancer: A review of the updated literature
por: Shirouzu, Kazuo, et al.
Publicado: (2017)

Preventive effects of amino-acid-rich elemental diet Elental(®) on chemotherapy-induced oral mucositis in patients with colorectal cancer: a prospective pilot study
por: Ogata, Yutaka, et al.
Publicado: (2015)

A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy (OX‐IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2021)

A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer
por: Ikoma, Tatsuki, et al.
Publicado: (2023)

Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report
por: Kamei, Hideki, et al.
Publicado: (2016)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

Benefit of the measurement of mesorectal extension in patients with pT3N1-2 rectal cancer without pre-operative chemoradiotherapy: Post-operative treatment strategy
por: AKAGI, YOSHITO, et al.
Publicado: (2013)

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study
por: Wang, Junxiao, et al.
Publicado: (2023)

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings
por: Wilson, S, et al.
Publicado: (2015)

First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI)
por: EICHLER, K., et al.
Publicado: (2012)

Randomized phase II study of cetuximab versus irinotecan and cetuximab in patients with chemo-refractory KRAS codon G13D metastatic colorectal cancer (G13D-study)
por: Nakamura, Masato, et al.
Publicado: (2016)

Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma
por: Akahori, Takahiro, et al.
Publicado: (2019)

A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
por: Kikuchi, Koji, et al.
Publicado: (2022)

Case report: Changes in serum bevacizumab concentration in a hemodialysis patient with unresectable colorectal cancer treated with FOLFIRI plus bevacizumab
por: Tanaka, Toshimitsu, et al.
Publicado: (2022)

Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer
por: Nakano, Shintaro, et al.
Publicado: (2022)

Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report
por: Martin, Robert CG, et al.
Publicado: (2009)

Long-term survival of a patient with small cell carcinoma of the stomach with metachronous lung metastases treated by multimodal therapy: a case report
por: Aoyagi, Keishiro, et al.
Publicado: (2015)

A Case of Gastric Cancer with Neuroendocrine Carcinoma, Signet Ring Cell Carcinoma Components, and Intramural Metastases
por: Aoyagi, Keishiro, et al.
Publicado: (2016)

Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer
por: Hashimoto, Kousuke, et al.
Publicado: (2013)

Diversity and shared T-cell receptor repertoire analysis in esophageal squamous cell carcinoma
por: Sudo, Tomoya, et al.
Publicado: (2021)

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
por: Hong, Y S, et al.
Publicado: (2006)

Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases
por: Barone, C, et al.
Publicado: (2007)

Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments]
por: Yokoyama, A., et al.
Publicado: (1998)

Irinotecan eluting beads-transarterial chemoembolization using Callispheres® microspheres is an effective and safe approach in treating unresectable colorectal cancer liver metastases
por: Zhao, Guangsheng, et al.
Publicado: (2021)

Surgery for Killian-Jamieson diverticulum: a report of two cases
por: Saisho, Kohei, et al.
Publicado: (2020)

Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
por: Souglakos, J, et al.
Publicado: (2012)

Scheduled Interval Trans-Catheter Arterial Chemoembolization Followed by Radiation Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Yu, Jeong Il, et al.
Publicado: (2012)

Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer
por: Iwai, Naoto, et al.
Publicado: (2020)

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
por: Yamada, M, et al.
Publicado: (2002)

Phase I Study of Celecoxib with Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer
por: Komaki, Ritsuko, et al.
Publicado: (2011)

Chemoembolization with CalliSpheres drug-eluting beads loaded with irinotecan in the treatment of unresectable colorectal cancer liver metastases: preliminary results in 16 cases
por: Kong, Jian, et al.
Publicado: (2019)

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial
por: Skof, Erik, et al.
Publicado: (2009)

Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
por: Sekine, I, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_1nic98hd76mtbl03m61n37q7l9